Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Genetic Diversity Explains Obesity Risk DifferencesCross-ancestry Study Identifies Novel Obesity Genes.
Meniscal Tear and OA Pain Improved by Home ExerciseHome Exercise Proves Effective for Knee.
AI ECG Model Outperforms Standard STEMI TriageNovel AI ECG Model Outperforms Standard.
New Software Transforms Real-Time Pathogen SurveillanceReal-Time Pathogen Surveillance Software Transforms Environmental.
Bright Nights May Increase Stroke, Heart Failures in AdultsBright Nights are tied to increased.
Cannabis Use Linked to Regular Tobacco in US YouthCannabis Use and Tobacco Risk: A.
Mediterranean Diet Reduces Endometriosis Risk in WomenMediterranean Diet and Endometriosis: A Promising.
Night Shifts May Trigger Irritable Bowel Syndrome (IBS)Night Shifts and Digestive Health: Linking.
Blood test shows promise for faster ALS diagnosisSummary / Key Points A UCLA.
Caraway seed chemistry yields anticonvulsant leadsA team led by UNLV researchers.
Leave a Comment